The large Norges Bank trim may reflect strategic rebalancing or risk reduction, but the concurrent accumulation by multiple active asset managers (Woodline, Rhumbline, Legal & General) suggests a potential value or catalyst-based thesis. Combine with recent insider buying and strong analyst consensus (82% bullish) to gauge conviction. Monitor next earnings for fundamental catalyst that could resolve the divergent views.
Executive Summary
Q3 2024 13F filings show mixed institutional activity in Fractyl Health (GUTS): four funds (Woodline Partners, Schwab, Rhumbline, Legal & General) added shares, but Norges Bank slashed its position by 68%, driving net institutional selling of ~$1.1M. The cluster suggests divergent views on the surgical-medical-device company's near-term prospects.
Key Financial Metrics
Institutional Positions
Net institutional flow: -$1.1M
▲ Buyers (4)
| Institution | Action | Change | Position Value | Value Δ |
|---|---|---|---|---|
| Woodline Partners | ADD | +61.8% | $1.1M | -$45.7K |
| Schwab | ADD | +56.9% | $204.0K | -$15.4K |
| Rhumbline Advisers | ADD | +99.3% | $37.0K | $6.0K |
| Legal & General Group | DOUBLED | +209.3% | $8.0K | $4.0K |
▼ Sellers (1)
| Institution | Action | Change | Prev Value | Value Δ |
|---|---|---|---|---|
| Norges Bank | TRIM | -68.1% | $1.3M | -$1.1M |
Key Facts
- Norges Bank trimmed 68.1% of its GUTS holdings, selling ~213.5K shares and reducing its position from $1.3M to $253K.
- Woodline Partners added 61.8% (+160.4K shares), maintaining a $1.1M position.
- Schwab increased by 56.9% (+29.3K shares), Rhumbline Advisers by 99.3%, and Legal & General Group doubled its position.
- Four buyers added shares but total buyer value declined slightly to $1.3M due to stock price movement; the single seller's reduction dominated net dollar flow.
- Recent insider buying of $44K (two buys in last 30 days) provides a modest counterweight to institutional selling.
Financial Impact
Net institutional outflow of approximately $1.1M, with $1.3M in total buyer positions offset by $1.3M in seller divestment (primarily Norges Bank). Net dollar change across all filers is -$1.14M.
Risk Factors
- 13F data is 45+ days old and positions may have been unwound since quarter-end.
- Dominant seller (Norges Bank) is a sophisticated sovereign fund; their reduction may signal fundamental concerns not yet public.
- Small-cap medtech stocks face clinical/regulatory binary risks that could amplify moves in either direction.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 institutional 13F filing from SEC EDGAR.
| Document | Accession Number |
|---|---|
| INST-CLUSTER Data (Synthetic) | inst-cluster-GUTS-2024-Q3 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | 8-K | $1.13 | awaiting T+5 | — | — |
Oct 16, 2026 10d ago | 8-K | $1.55 $1.08 | ▼ −30.32% | ▼ −30.42% | — |
Oct 13, 2026 12d ago | SC 13G | $4.03 $1.33 | ▼ −66.96% | ▼ −65.80% | — |
Aug 10, 2026 10w ago | 8-K | $0.7018 $0.7171 | ▲ +2.18% | ▲ +2.58% | — |
Aug 10, 2026 10w ago | Press Release | $0.7018 $0.7171 | ▲ +2.18% | ▲ +2.58% | — |
Jul 15, 2026 14w ago | 8-K | $0.9100 $0.7580 | ▼ −16.70% | ▼ −15.72% | — |
Jun 12, 2026 19w ago | Institutional Cluster | $0.8500 $0.8583 | ▲ +0.98% | ▲ +0.30% | — |
Jun 11, 2026 19w ago | Insider Cluster | $0.8500 $0.8583 | ▲ +0.98% | ▲ +0.30% | — |
Jun 11, 2026 19w ago | Institutional Cluster | $0.7239 $0.8500 | ▲ +17.42% | ▲ +16.99% | — |
Jun 4, 2026 20w ago | 8-K | $0.7340 $0.7240 | ▼ −1.36% | ▲ +1.19% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers